Edition:
United States

Catabasis Pharmaceuticals Inc (CATB.OQ)

CATB.OQ on NASDAQ Stock Exchange Global Market

0.77USD
4:00pm EDT
Change (% chg)

$0.01 (+0.68%)
Prev Close
$0.76
Open
$0.77
Day's High
$0.79
Day's Low
$0.75
Volume
20,975
Avg. Vol
162,447
52-wk High
$3.78
52-wk Low
$0.61

Latest Key Developments (Source: Significant Developments)

Catabasis Pharmaceuticals Reports Q2 Loss Per Share $0.20
Thursday, 9 Aug 2018 08:05am EDT 

Aug 9 (Reuters) - Catabasis Pharmaceuticals Inc ::CATABASIS PHARMACEUTICALS REPORTS SECOND QUARTER 2018 FINANCIAL RESULTS AND REVIEWS BUSINESS PROGRESS.Q2 LOSS PER SHARE $0.20.Q2 EARNINGS PER SHARE VIEW $-0.23 -- THOMSON REUTERS I/B/E/S.AS OF JUNE 30, 2018, HAD CASH, CASH EQUIVALENTS OF $49.9 MILLION, COMPARED TO $17.0 MILLION AS OF MARCH 31, 2018.BASED ON CO'S CURRENT OPERATING PLAN, BELIEVES IT HAS SUFFICIENT CASH TO FUND OPERATIONS INTO Q2 2020.  Full Article

Catabasis Pharmaceuticals Presents New Edasalonexent Data
Wednesday, 25 Apr 2018 05:00pm EDT 

April 25 (Reuters) - Catabasis Pharmaceuticals Inc ::CATABASIS PHARMACEUTICALS PRESENTS NEW EDASALONEXENT DATA SHOWING SIGNIFICANTLY SLOWED DUCHENNE MUSCULAR DYSTROPHY DISEASE PROGRESSION AS MEASURED BY MRI THROUGH ONE YEAR OF TREATMENT.CATABASIS PHARMACEUTICALS INC - STATISTICALLY SIGNIFICANT IMPROVEMENTS IN MRI T2 RATE OF CHANGE.  Full Article

Catabasis Pharma Aligns Resources To Focus On Lead Program Edasalonexent
Tuesday, 17 Apr 2018 04:01pm EDT 

April 17 (Reuters) - Catabasis Pharmaceuticals Inc ::CATABASIS PHARMACEUTICALS ALIGNS RESOURCES TO FOCUS ON LEAD PROGRAM EDASALONEXENT FOR THE TREATMENT OF DUCHENNE MUSCULAR DYSTROPHY.CATABASIS PHARMACEUTICALS INC - STRATEGIC CORPORATE RESTRUCTURING SUPPORTS GOAL OF ADVANCING EDASALONEXENT TOWARDS POTENTIAL REGISTRATION.CATABASIS PHARMACEUTICALS INC - RESTRUCTURING WILL REDUCE COMPANY'S WORKFORCE BY APPROXIMATELY 42%.CATABASIS PHARMACEUTICALS INC - ESTIMATES ANNUALIZED SAVINGS OF APPROXIMATELY $3.3 MILLION IN PERSONNEL-RELATED COSTS.CATABASIS PHARMACEUTICALS INC - ESTIMATED ONE-TIME SEVERANCE AND RELATED COSTS OF APPROXIMATELY $1.0 MILLION IN Q2 OF 2018.  Full Article

Clarus Lifesciences II Lp Reports A 6.92 Pct Stake In Catabasis Pharmaceuticals As Of March 22
Wednesday, 4 Apr 2018 04:52pm EDT 

April 4 (Reuters) - Catabasis Pharmaceuticals Inc ::CLARUS LIFESCIENCES II LP REPORTS A 6.92 PCT STAKE IN CATABASIS PHARMACEUTICALS INC <<>> AS OF MARCH 22 - SEC FILING .CLARUS LIFESCIENCES II LP PREVIOUSLY REPORTED A 11.92 PERCENT STAKE IN CATABASIS PHARMACEUTICALS AS OF OCT. 31, 2017.  Full Article

Catabasis Pharmaceuticals Reports Q4 Loss Per Share $0.24
Thursday, 15 Mar 2018 04:10pm EDT 

March 15 (Reuters) - Catabasis Pharmaceuticals Inc ::CATABASIS PHARMACEUTICALS REPORTS FOURTH QUARTER AND FULL YEAR 2017 FINANCIAL RESULTS AND REVIEWS BUSINESS PROGRESS.Q4 LOSS PER SHARE $0.24.Q4 REVENUE $300,000.Q4 EARNINGS PER SHARE VIEW $-0.31 -- THOMSON REUTERS I/B/E/S.CATABASIS PHARMACEUTICALS - PLANS TO INITIATE A GLOBAL PHASE 3 TRIAL WITH EDASALONEXENT IN PATIENTS WITH DMD REGARDLESS OF MUTATION TYPE IN H1 2018.  Full Article

Catabasis Reports Edasalonexent Preserved Muscle Function And Substantially Slowed Duchenne Muscular Dystrophy Disease Progression
Tuesday, 13 Feb 2018 08:00am EST 

Feb 13 (Reuters) - Catabasis Pharmaceuticals Inc ::CATABASIS PHARMACEUTICALS REPORTS EDASALONEXENT PRESERVED MUSCLE FUNCTION AND SUBSTANTIALLY SLOWED DUCHENNE MUSCULAR DYSTROPHY DISEASE PROGRESSION THROUGH MORE THAN ONE YEAR OF TREATMENT.CATABASIS - PLANS TO INITIATE SINGLE GLOBAL PHASE 3 TRIAL WITH EDASALONEXENT IN PATIENTS WITH DMD REGARDLESS OF MUTATION TYPE IN FIRST HALF OF 2018.CATABASIS PHARMACEUTICALS - ‍EDASALONEXENT CONTINUED TO BE WELL TOLERATED WITH NO SAFETY SIGNALS OBSERVED IN TRIAL​.CATABASIS PHARMACEUTICALS INC - TOP-LINE RESULTS IN SINGLE GLOBAL PHASE 3 TRIAL WITH EDASALONEXENT IN PATIENTS EXPECTED IN 2020.  Full Article

Catabasis Pharmaceuticals reports third quarter financial results
Thursday, 9 Nov 2017 04:10pm EST 

Nov 9 (Reuters) - Catabasis Pharmaceuticals Inc :Catabasis Pharmaceuticals reports third quarter 2017 financial results and reviews business progress.Q3 loss per share $0.31.Q3 earnings per share view $-0.33 -- Thomson Reuters I/B/E/S.Catabasis Pharmaceuticals Inc - co's current operating plan provides for cash to fund operations through august 2018​.  Full Article

Catabasis Pharmaceuticals reports positive DMD drug data
Wednesday, 4 Oct 2017 04:30am EDT 

Oct 4 (Reuters) - Catabasis Pharmaceuticals Inc ::Catabasis Pharmaceuticals reports positive results from open-­label extension of phase 2 MoveDMD trial evaluating edasalonexent in duchenne muscular dystrophy.Catabasis Pharmaceuticals says edasalonexent substantially slowed duchenne muscular dystrophy disease progression through 36 weeks in phase 2 trial.Plans to initiate single global phase 3 trial with edasalonexent in patients with DMD regardless of mutation type in first half of 2018.Catabasis Pharmaceuticals says top-­line results from single global phase 3 trial with edasalonexent expected in 2020.Catabasis Pharmaceuticals says edasalonexent continued to be well tolerated with no safety signals observed to date in movedmd trial.  Full Article

Catabasis Pharmaceuticals reports positive results from phase 2 trial of medicine for progressive muscle degeneration disease
Wednesday, 4 Oct 2017 04:30am EDT 

Oct 4 (Reuters) - Catabasis Pharmaceuticals Inc : :Catabasis Pharmaceuticals reports positive results from open-label extension of phase 2 movedmd® trial evaluating Edasalonexent in duchenne muscular dystrophy and plans to initiate phase 3 clinical trial in first half 2018.Catabasis Pharmaceuticals Inc - ‍Edasalonexent substantially slowed duchenne muscular dystrophy disease progression through 36 weeks​.Catabasis - ‍plans to initiate a single global phase 3 trial with Edasalonexent in patients with DMD regardless of mutation type in first half of 2018​.Catabasis Pharmaceuticals Inc - ‍expects to report top-line results from single global phase 3 trial in DMD in 2020​.Catabasis Pharmaceuticals Inc - ‍heart rate of boys with DMD treated with Edasalonexent decreased toward "age-normative values" during treatment​.Catabasis - ‍believe clinical heart rate observations in boys with DMD treated with Edasalonexent​ "are intriguing and warrant follow-up".  Full Article

Catabasis Pharmaceuticals Q2 loss per share $0.32
Thursday, 10 Aug 2017 04:10pm EDT 

Aug 10 (Reuters) - Catabasis Pharmaceuticals Inc :Catabasis Pharmaceuticals reports second quarter 2017 financial results and reviews business progress.Q2 loss per share $0.32.Q2 earnings per share view $-0.40 -- Thomson Reuters I/B/E/S.Catabasis Pharmaceuticals Inc - ‍continue to advance open-label extension and expect to share 24-week edasalonexent results in Q3.Catabasis Pharmaceuticals Inc - ‍phase 3 clinical trial plan for edasalonexent in second half of 2017​.Catabasis Pharmaceuticals Inc - ‍as of June 30, cash and cash equivalents of $29.4 million, versus $31.8 million last quarter.Catabasis Pharmaceuticals Inc - ‍Catabasis expects that its current operating plan provides for cash to fund operations through August, 2018​.  Full Article

BRIEF-Catabasis Pharmaceuticals Reports Q1 Loss Per Share $0.29

* CATABASIS PHARMACEUTICALS REPORTS FIRST QUARTER 2018 FINANCIAL RESULTS AND REVIEWS BUSINESS PROGRESS